



Pixium Vision appoints Dr Guillaume Buc as Chief Technology Officer

Paris, France, July 1, 2013 – Pixium Vision (“Pixium”), a developer of innovative retinal implant systems that aim to restore vision in the blind, is pleased to announce the appointment of Dr Guillaume Buc as Chief Technology Officer (“CTO”). Dr Buc will lead Pixium’s product development activities focused on the Intelligent Retinal Implant Systems (IRIS).

Pixium’s first device, IRIS1, uses an epi-retinal implant and is currently in clinical trials, which are expected to report in 2014 and form the basis of an application for CE Mark later in the year. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing IRIS3, a sub-retinal implant system based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2.

Dr Buc has over 15 years of experience in senior technology development and management roles at GE Healthcare (“GEHC”) Europe. Since 2010, he served as CTO at GEHC’s Interventional Cardiology business where he was responsible for managing the product development cycle from advanced studies through to product finalization. Prior to that, he spent two years as Global Manager of GEHC Vascular Software division responsible for the development of GE Cardio-Vascular imaging systems.

Dr Buc holds Eng degrees (MSc equivalent) in Image Processing, Computer Science, and in Applied Mathematics, Computer Science from Ecole Nationale Supérieure des Télécommunications de Paris and Ecole Polytechnique, respectively.

Dr Bernard Gilly, Chairman and CEO, commented: “I am delighted to welcome Guillaume to Pixium in the position of Chief Technology Officer, significantly strengthening our product development team during what is a very exciting period for the business. The initial results of the current clinical trial with IRIS1, if positive, should provide the basis for a CE Mark application in 2014 and the data generated will help to guide the development of future generations of our retinal implant devices. The expertise and experience Guillaume adds to our team will enable Pixium to accelerate the development of our multiple IRIS devices towards commercialization with the aim of providing a potentially life-changing benefit to blind people.”

For more information, please go to www.pixium-vision.com

Contacts:

Bernard Gilly, Chairman and CEO
bgilly@pixium-vision.com
+33 1 76 21 47 30